Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1632 1651
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17428670 | TXNIP AND LDHB COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES | Final Rejection | President and Fellows of Harvard College |
| 17602987 | METHODS FOR TREATING INHERITED EYE DEFECTS | Non-Final OA | The Regents of the University of California |
| 17496391 | METHODS AND SYSTEMS FOR IMPROVING CELLS FOR USE IN THERAPY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18038630 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17433658 | COMPOSITIONS, METHODS, AND KITS FOR DELIVERY OF POLYRIBONUCLEOTIDES | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17909705 | METHODS OF TREATING HYPERGLYCEMIA AND SUPPRESSING ONSET OF TYPE 1 DIABETES | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18146109 | PRODUCTION METHOD FOR SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS AND PRODUCTION METHOD FOR CELL PREPARATION FOR JOINT MEDICAL TREATMENT | Final Rejection | National University Corporation Tokyo Medical and Dental University |
| 18000865 | DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION | Non-Final OA | EMORY UNIVERSITY |
| 17830637 | BIOLOGICAL LIBRARIES AND METHODS OF PREPARING AND USING SAME | Non-Final OA | UNM RAINFOREST INNOVATIONS |
| 17906098 | MODIFIED ARRESTIN-1 TO ENHANCE PHOTORECEPTOR SURVIVAL IN RETINAL DISEASE | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 19003915 | ALLOGENEIC STEM CELL COMPOSITIONS AND METHODS OF TREATMENT | Non-Final OA | NEXTCELL PHARMA AB |
| 17793506 | METHODS OF TREATING FRAGILE X SYNDROME WITH REELIN | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18001828 | Genetically Modified Bovine Herpesvirus Type 1 (BHV-1) for use to Treat Cancer | Non-Final OA | McMaster University |
| 17783937 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17998857 | EXOSOME-DERIVED PIWI-INTERACTING RNA AND METHODS OF USE THEREOF | Final Rejection | Cedars-Sinai Medical Center |
| 18043064 | PRIMED PLACENTAL TISSUE AND USES IN REGENERATIVE MEDICINE | Non-Final OA | OSIRIS THERAPEUTICS, INC. |
| 18035685 | SYNERGISTIC STEM CELL-BASED MEDICATION FOR TREATING MYOCARDIAL INFARCTION AND RELATED APPLICATION | Non-Final OA | SOOCHOW UNIVERSITY |
| 18124656 | HUMAN FACILITATING CELLS | Final Rejection | University of Louisville Research Foundation, Inc. |
| 17862892 | 3-D BIOPRINTING COMPRISING BIOLOGICALLY-RELEVANT MATERIALS AND RELATED METHODS | Final Rejection | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 17769524 | METHODS FOR MODULATING HUMAN L1 RETROTRANSPOSONS RNA AND COMPOSITIONS FOR USE THEREIN | Final Rejection | Salk Institute For Biological Studies |
| 18129399 | IN UTERO TRANSPLANTATION OF FACTOR VIII-EXPRESSING CELLS FOR TREATMENT OF HEMOPHILIA | Non-Final OA | Children's Healthcare of Atlanta, Inc. |
| 18264831 | METHOD FOR MODULATING AFUCOSLYATION OF AN ANTIBODY PRODUCT | Non-Final OA | LONZA BIOLOGICS PLC |
| 18300210 | ENHANCEMENT OF CARTILAGE REGENERATIVE ACTIVITY OF STEM CELL POPULATIONS BASED ON REDUCTION OF INTRA-ARTICULAR CELLULAR MATERIAL | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18351665 | PHARMACEUTICAL COMBINATION FOR MOOD DISORDERS | Non-Final OA | INSTITUTO NACIONAL DE PSIQUIATRÍA "RAMÓN DE LA FUENTE MUÑIZ" |
| 18267957 | PRE-TREATMENT OF MSC WITH PPARB/DELTA AGONIST FOR TREATMENT OF ISCHEMIA-REPERFUSION INJURY | Non-Final OA | Centre Hospitalier Universitaire de Montpellier |
| 18041303 | A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE | Non-Final OA | Mesoblast International Sárl |
| 17906160 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE I | Non-Final OA | Mesoblast International Sárl |
| 17422737 | AAV-MEDIATED GENE THERAPY RESTORING THE OTOFERLIN GENE | Non-Final OA | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
| 18206091 | PREPARATION METHOD FOR CANINE WHOLE BLOOD HEMATOPOIETIC STEM CELLS | Non-Final OA | Qingdao Jinmotang Biotechnology Co., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy